Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.
Theodore R.  Samuels, II net worth and biography

Theodore Samuels, II Biography and Net Worth

Mr. Samuels, age 68, has been the Lead Independent Director of Bristol-Myers Squibb since May 2021 and has served on the Board since February 2017. With more than 35 years in the financial industry, Mr. Samuels brings to the Board extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making. Mr. Samuels was president of Capital Guardian Trust Company from 2010 until 2016 and a global equity portfolio manager at Capital Group, one of the most prominent investment management organizations in the world from 1990 until 2016. While at Capital Group, he served on numerous management and investment committees, with an eye towards long-term shareholder value creation.

Mr. Samuels currently serves as a director at Centene Corporation and Iron Mountain Inc., and is a former director of Perrigo Company, PLC.

What is Theodore R. Samuels, II's net worth?

The estimated net worth of Theodore R. Samuels, II is at least $1.81 million as of November 20th, 2023. Mr. Samuels, II owns 35,500 shares of Bristol-Myers Squibb stock worth more than $1,806,595 as of March 3rd. This net worth evaluation does not reflect any other assets that Mr. Samuels, II may own. Learn More about Theodore R. Samuels, II's net worth.

How do I contact Theodore R. Samuels, II?

The corporate mailing address for Mr. Samuels, II and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Theodore R. Samuels, II's contact information.

Has Theodore R. Samuels, II been buying or selling shares of Bristol-Myers Squibb?

Theodore R. Samuels, II has not been actively trading shares of Bristol-Myers Squibb within the last three months. Most recently, on Monday, November 20th, Theodore R. Samuels II bought 8,500 shares of Bristol-Myers Squibb stock. The stock was acquired at an average cost of $49.81 per share, with a total value of $423,385.00. Following the completion of the transaction, the director now directly owns 35,500 shares of the company's stock, valued at $1,768,255. Learn More on Theodore R. Samuels, II's trading history.

Who are Bristol-Myers Squibb's active insiders?

Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.

Are insiders buying or selling shares of Bristol-Myers Squibb?

During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 69,103 shares worth more than $4,525,215.08. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.

Information on this page was last updated on 12/5/2023.

Theodore R. Samuels, II Insider Trading History at Bristol-Myers Squibb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2023Buy8,500$49.81$423,385.0035,500View SEC Filing Icon  
5/16/2019Buy5,000$47.29$236,450.0027,000View SEC Filing Icon  
12/15/2017Buy4,000$62.30$249,200.0022,000View SEC Filing Icon  
8/2/2017Buy6,000$55.94$335,640.0018,000View SEC Filing Icon  
2/27/2017Buy12,000$56.77$681,240.0012,000View SEC Filing Icon  
See Full Table

Theodore R. Samuels, II Buying and Selling Activity at Bristol-Myers Squibb

This chart shows Theodore R Samuels II's buying and selling at Bristol-Myers Squibb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York.
Read More

Today's Range

Now: $50.89
Low: $50.44
High: $51.08

50 Day Range

MA: $50.31
Low: $48.00
High: $52.79

2 Week Range

Now: $50.89
Low: $47.58
High: $71.07

Volume

10,892,290 shs

Average Volume

13,595,074 shs

Market Capitalization

$102.91 billion

P/E Ratio

13.18

Dividend Yield

4.72%

Beta

0.38
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.